IDH1 and cancer: In addition, ivosidenib, an inhibitor of IDH1R132 mutants, has been approved by the FDA, for the treatment of acute myeloid leukemia (AML) patients harboring these variants [137], while its effectiveness in other IDH1-deficient cancer types is currently being tested in several ongoing clinical trials (e.g., advanced and metastatic cholangiocarcinoma/NCT02989857, chondrosarcoma/NCT04278781, cholangiocarcinoma—chondrosarcoma—glioma—other advanced solid tumors/NCT02073994, recurrent ependymoma—recurrent ewing sarcoma—recurrent hepatoblastoma/NCT04195555, etc.).